Top-Rated StocksTop-RatedNASDAQ:NEO NeoGenomics (NEO) Stock Price, News & Analysis $14.88 -0.20 (-1.33%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$14.66▼$15.5150-Day Range$13.01▼$15.8452-Week Range$11.03▼$21.22Volume833,547 shsAverage Volume834,041 shsMarket Capitalization$1.90 billionP/E RatioN/ADividend YieldN/APrice Target$19.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NeoGenomics alerts: Email Address NeoGenomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside32.9% Upside$19.78 Price TargetShort InterestHealthy4.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.21) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.74 out of 5 starsMedical Sector252nd out of 936 stocksTesting Laboratories Industry1st out of 2 stocks 4.5 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeoGenomics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NeoGenomics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.08% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in NeoGenomics has recently decreased by 5.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 3.1 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for NeoGenomics this week, compared to 3 articles on an average week.Search Interest8 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeoGenomics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.21) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -22.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -22.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about NeoGenomics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About NeoGenomics Stock (NASDAQ:NEO)NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Read More NEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEO Stock News HeadlinesJuly 26 at 2:34 AM | finance.yahoo.comWorldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 29% p.a., Reaching $10.1B by 2029 – Market Report by DeciBio Consulting LLCJuly 23 at 4:35 PM | ca.finance.yahoo.comNEO Aug 2024 20.000 putJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 22, 2024 | finance.yahoo.comNeoGenomics (NASDAQ:NEO) shareholders have endured a 68% loss from investing in the stock three years agoJuly 22, 2024 | americanbankingnews.comNeoGenomics (NEO) Scheduled to Post Earnings on MondayJuly 20, 2024 | msn.comIs NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years?June 13, 2024 | businesswire.comFort Myers' Mayor to Proclaim June as NeoGenomics' Commitment to Cancer MonthJune 10, 2024 | globenewswire.comPress release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global MarketingJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 29, 2024 | bizjournals.comAlbuquerque's Indica Labs lands FDA clearanceMay 28, 2024 | businesswire.comNeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment ManagementMay 11, 2024 | finance.yahoo.comNeoGenomics, Inc. (NEO)May 10, 2024 | benzinga.comNeoGenomics Earnings Analysis: Q1 RecapMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for NeoGenomics Amid Strong Q1 Performance and Growth ProspectsMay 2, 2024 | finance.yahoo.comNeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comNeoGenomics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 1, 2024 | au.finance.yahoo.comQ1 2024 Neogenomics Inc Earnings CallMay 1, 2024 | msn.comNeoGenomics in Fort Myers and Herc in Bonita announce earnings. How did they do?See More Headlines Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Next Earnings (Confirmed)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Testing laboratories Sub-IndustryN/A Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$19.78 High Stock Price Target$26.00 Low Stock Price Target$17.00 Potential Upside/Downside+23.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,970,000.00 Net Margins-13.79% Pretax Margin-14.91% Return on Equity-3.54% Return on Assets-1.99% Debt Debt-to-Equity Ratio0.58 Current Ratio7.48 Quick Ratio7.22 Sales & Book Value Annual Sales$591.64 million Price / Sales3.45 Cash Flow$0.30 per share Price / Cash Flow53.77 Book Value$7.39 per share Price / Book2.16Miscellaneous Outstanding Shares127,710,000Free Float126,052,000Market Cap$2.04 billion OptionableOptionable Beta1.19 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Christopher Michael Smith BSc (Age 61)CEO & Director Comp: $2.86MMr. Jeffrey S. Sherman M.B.A. (Age 58)Chief Financial Officer Comp: $1.17MMr. Vishal Sikri (Age 48)President of Advanced Diagnostics Comp: $1.08MMs. Melody Harris Esq. (Age 57)J.D., President & COO of Informatics Comp: $1.4MMr. Warren Stone (Age 51)Chief Commercial Officer Comp: $1.42MMs. Kendra SweeneyVice President of Investor Relations & CommunicationsMs. Alicia Olivo (Age 40)Executive VP of Business Development, General Counsel & Corporate Secretary Mr. Hutan Hashemi J.D. (Age 45)Chief Compliance Officer Dr. Derek Lyle M.D.Chief Medical OfficerMr. Gary PassmanChief Culture OfficerMore ExecutivesKey CompetitorsApplied DNA SciencesNASDAQ:APDNUL SolutionsNYSE:ULSPenumbraNYSE:PENBlueprint MedicinesNASDAQ:BPMCIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 16,023 shares on 7/26/2024Ownership: 0.747%Allspring Global Investments Holdings LLCBought 7,793 shares on 7/26/2024Ownership: 0.023%Louisiana State Employees Retirement SystemBought 1,200 shares on 7/24/2024Ownership: 0.050%Oak Family Advisors LLCBought 1,454 shares on 7/23/2024Ownership: 0.085%Blue Trust Inc.Bought 1,206 shares on 7/18/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions NEO Stock Analysis - Frequently Asked Questions How have NEO shares performed this year? NeoGenomics' stock was trading at $16.18 at the beginning of 2024. Since then, NEO shares have decreased by 8.0% and is now trading at $14.88. View the best growth stocks for 2024 here. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Tuesday, April, 30th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The medical research company had revenue of $156.24 million for the quarter, compared to the consensus estimate of $149.82 million. NeoGenomics had a negative net margin of 13.79% and a negative trailing twelve-month return on equity of 3.54%. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. Does NeoGenomics have any subsidiaries? NeoGenomics subsidiaries include Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and others. Who are NeoGenomics' major shareholders? Top institutional shareholders of NeoGenomics include Bank of New York Mellon Corp (0.75%), Oak Family Advisors LLC (0.09%), Louisiana State Employees Retirement System (0.05%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Alicia C Olivo, William Bonello, Mark Mallon, Douglas Matthew Brown and Kathryn B Mckenzie. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL) and Micron Technology (MU). This page (NASDAQ:NEO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
